DeepMatter Group Plc has signed a trials agreement with Aurigene Pharmaceutical Services Limited to supply its DigitalGlassware platform. Aurigene Pharmaceutical Services is a fully integrated Contract Research, Development and Manufacturing Organization providing a wide range of services for small and large molecule. DeepMatter will provide its DigitalGlassware platform to Aurigene Pharmaceutical Services to help screen, develop and scale up chemistry procedures and to accelerate custom drug discovery and development projects. Aurigene Pharmaceutical Services seeks to evaluate the technology to find efficiency and productivity gains through deeper data insights via collated aggregated data streams to better understand difficult synthetic routes and to foster active data sharing capabilities. The technology will help scan every reaction parameter and accelerate failed reaction diagnostics. Through this project Aurigene Pharmaceutical Services reinforces its focus to provide faster and efficient chemistry services to its customers and thus accelerating the drug discovery and development process. DigitalGlassware comprises a cloud-based software platform allowing scientists to easily bring together digitised synthesis protocols (recipes) and contextualised time-course sensor streams from a range of analytical instrumentation, in real-time.